Cheng-Hao Chuang

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Systematic Review

Psychometric Properties

Epidermal Growth Factor Receptor

Chronic Myeloid Leukemia

Top Venues

The Kaohsiung journal of medical sciences

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Chia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, Kuan-Li Wu, Yu-Chen Tsai, Cheng-Hao Chuang, Chung-Wen Huang, Chin-Ling Chen, Chih-Jen Yang, Inn-Wen Chong
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung. The Kaohsiung journal of medical sciences 40 (5) (2024)
Chia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, Kuan-Li Wu, Yu-Chen Tsai, Cheng-Hao Chuang, Chung-Wen Huang, Chin-Ling Chen, Chih-Jen Yang, Inn-Wen Chong
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung. The Kaohsiung journal of medical sciences (2024)
Chia-Yu Kuo, Ming-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, Kuan-Li Wu, Yu-Chen Tsai, Cheng-Hao Chuang, Chung-Wen Huang, Chin-Ling Chen, Chih-Jen Yang, Inn-Wen Chong
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung. The Kaohsiung journal of medical sciences 40 (5) (2024)
Ming-Ju Tsai, Yu-Kang Tu, Juei-Yang Ma, Yu-Chen Tsai, Kuan-Li Wu, Mei-Hsuan Lee, Chia-Yu Kuo, Cheng-Hao Chuang, Tai-Huang Lee, Yen-Lung Lee, Chun-Ming Huang, Mei-Chiou Shen, Chih-Jen Yang, Inn-Wen Chong
Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR -Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib. Cancers 15 (7) (2023)
Sheng-Bin Fan, Ming-Ju Tsai, Mei-Chuan Kuo, Cheng-Hao Chuang
Therapeutic plasma exchange for refractory vaccine-induced immune thrombotic thrombocytopenia. The Kaohsiung journal of medical sciences 38 (8) (2022)
Hsiang-Hao Chuang, Yen-Yi Zhen, Yu-Chen Tsai, Cheng-Hao Chuang, Michael Hsiao, Ming-Shyan Huang, Chih-Jen Yang
FAK in Cancer: From Mechanisms to Therapeutic Strategies. International journal of molecular sciences 23 (3) (2022)
Chia-Yu Kuo, Ming-Ju Tsai, Yu-Kang Tu, Kuan-Li Wu, Ying-Ming Tsai, Yu-Chen Tsai, Cheng-Hao Chuang, Tai-Huang Lee, Huang-Chi Chen, Chih-Jen Yang, Inn-Wen Chong
Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. Cancers 15 (1) (2022)
Hsiang-Hao Chuang, Ming-Shyan Huang, Yen-Yi Zhen, Cheng-Hao Chuang, Ying-Ray Lee, Michael Hsiao, Chih-Jen Yang
FAK Executes Anti-Senescence via Regulating EZH2 Signaling in Non-Small Cell Lung Cancer Cells. Biomedicines 10 (8) (2022)
Chia-Yu Kuo, Ming-Ju Tsai, Yu-Kang Tu, Kuan-Li Wu, Ying-Ming Tsai, Yu-Chen Tsai, Cheng-Hao Chuang, Tai-Huang Lee, Huang-Chi Chen, Chih-Jen Yang, Inn-Wen Chong
Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. Cancers 15 (1) (2022)
Chia-Yu Kuo, Ming-Ju Tsai, Yu-Kang Tu, Kuan-Li Wu, Ying-Ming Tsai, Yu-Chen Tsai, Cheng-Hao Chuang, Tai-Huang Lee, Huang-Chi Chen, Chih-Jen Yang, Inn-Wen Chong
Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. Cancers 15 (1) (2022)
Cheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, Yu-Chen Tsai, Kuan-Li Wu, I-Hua Chen, Kung-Chao Chen, Jui-Ying Lee, Yong-Chieh Chang, Chin-Ling Chen, Yu-Kang Tu, Chih-Jen Yang, Chih-Jen Yang, Inn-Wen Chong
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer. Cancers 13 (8) (2021)
Kuan-Li Wu, Hsiao-Ling Chen, Ying-Ming Tsai, Tai-Huang Lee, Hsiu-Mei Chang, Yu-Chen Tsai, Cheng-Hao Chuang, Yong-Chieh Chang, Chin-Ling Chen, Chih-Jen Yang, Yu-Kang Tu, Inn-Wen Chong
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis. Journal of clinical medicine 10 (19) (2021)
Ming-Ju Tsai, Wei-An Chang, Cheng-Hao Chuang, Kuan-Li Wu, Chih-Hung Cheng, Chau-Chyun Sheu, Ya-Ling Hsu, Jen-Yu Hung
Cysteinyl Leukotriene Pathway and Cancer. International journal of molecular sciences 23 (1) (2021)
Yu-Chen Tsai, Hsiao-Ling Chen, Tai-Huang Lee, Hsiu-Mei Chang, Kuan-Li Wu, Cheng-Hao Chuang, Yong-Chieh Chang, Chin-Ling Chen, Yu-Kang Tu, Chih-Jen Yang, Inn-Wen Chong
Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis. Cancers 14 (1) (2021)